A Game-Changer for Diabetes: Polymer Delivers Insulin Painlessly Through Skin
November 25, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
Millipred, Pediapred, Flopred, Orapred
Synonyms :
prednisolone
Class :
Corticosteroids
Brand Name :
Millipred, Pediapred, Flopred, Orapred
Synonyms :
prednisolone
Class :
Corticosteroids
Dosage Forms & Strengths
Tablet, orally disintegrating
10mg
15mg
30mg
tablet, dose pack
5mg ([21 tabs] 6 days)
5mg ([48 tabs] 12 days)
tablet
5mg
oral solution
5mg/5mL
10mg/5mL
15mg/5mL
20mg/5mL
25mg/5mL
200mg/day orally for one week, then 80mg orally every alternate day for one month
5-7.5mg orally every day
Chronic Obstructive Pulmonary DiseaseÂ
Indicated for Acute exacerbation of COPD:
30-40mg orally every day for 10-14 days
Off-label:
40
mg
Orally 
every day
28
days
; then taper off for 2 to 4 weeks
Dosage Forms & Strengths
Tablet, orally disintegrating
10mg
15mg
30mg
tablet, dose pack
5mg ([21 tabs] 6 days)
5mg ( [48 tabs] 12 days)
tablet
5mg
oral solution
5mg/5mL
10mg/5mL
15mg/5mL
20mg/5mL
25mg/5mL
Indicated for acute asthma:
1-2mg/kg/day in a single dose or divided every 12 hours for 3-5 days
The first four weeks of treatment is 60 mg/m²/day or 2 mg/kg/day taken orally, divided into doses every 8 hours until urine is protein-free for three consecutive days. The treatment should not exceed 28 days, and the maximum daily dose should not exceed 80 mg
Subsequent four weeks: 40 mg/m²/day or 1-1.5 mg/kg/day orally every alternate day
Refer adult dosing
may increase the immunosuppressive effect of corticosteroids
may increase the immunosuppressive effect of corticosteroids
may diminish the therapeutic effect of corticosteroids
may increase the immunosuppressive effect of corticosteroids
may diminish the therapeutic effect of corticosteroids
may diminish the therapeutic effect of corticosteroids
may diminish the therapeutic effect of corticosteroids
may diminish the therapeutic effect of corticosteroids
may diminish the bioavailability of corticosteroids
may diminish the bioavailability of corticosteroids
may diminish the bioavailability of corticosteroids
may diminish the bioavailability of corticosteroids
may diminish the bioavailability of corticosteroids
may increase the neuromuscular effect of corticosteroids
may increase the neuromuscular effect of corticosteroids
may increase the neuromuscular effect of corticosteroids
may increase the neuromuscular effect of corticosteroids
may increase the neuromuscular effect of corticosteroids
may increase the immunosuppressive effect of corticosteroids
measles, mumps, rubella, and varicella vaccine, live (Rx)
may increase the adverse effect of corticosteroids
measles mumps and rubella vaccine, live
may increase the adverse effect of corticosteroids
may increase the adverse effect of corticosteroids
vaccinia immune globulin intravenous (Rx)
may increase the adverse effect of corticosteroids
may increase the adverse effect of corticosteroids
may increase the serum concentration of each other when combined
may increase the serum concentration of each other when combined
may increase the serum concentration of each other when combined
may increase the serum concentration of each other when combined
may increase the serum concentration of each other when combined
may diminish the concentration of serum when combined with hormonal contraceptives
may diminish the concentration of serum when combined with hormonal contraceptives
may diminish the concentration of serum when combined with hormonal contraceptives
may diminish the concentration of serum when combined with hormonal contraceptives
may diminish the concentration of serum when combined with hormonal contraceptives
CYP3A4 Inducers: they may diminish the serum concentration of hormonal contraceptives
CYP3A4 Inducers: they may diminish the serum concentration of hormonal contraceptives
may diminish the serum concentration when combined with hormonal contraceptives
may diminish the serum concentration when combined with hormonal contraceptives
may diminish the serum concentration when combined with hormonal contraceptives
belumosudil :they may diminish the serum concentration of CYP3A4 Inducers
clopidogrel: they may enhance serum concentrations of CYP2C19 Inducers
etoposide: they may diminish the serum concentration of CYP3A4 inducers
atogepant: they may diminish the serum concentration of CYP3A4 Inducers
erdafitinib: they may diminish the serum concentration of CYP3A4 Inducers
praziquantel: they may diminish the serum concentration of CYP3A4 Inducers
ubrogepant: they may diminish the serum concentration of CYP3A4 Inducers
zanubrutinib: they may diminish the serum concentration of CYP3A4 Inducers
empagliflozin and linagliptinÂ
may diminish the serum concentration when combined
may diminish the concentration of serum when combined with daclatasvir
may diminish the concentration of serum when combined with duvelisib
may diminish the concentration of serum when combined with ganaxolone
may diminish the concentration of serum when combined with glasdegib
may diminish the concentration of serum when combined with guanfacine
may diminish the concentration of serum when combined with hormonal contraceptives
may diminish the concentration of serum when combined with hormonal contraceptives
may diminish the concentration of serum when combined with hormonal contraceptives
may diminish the concentration of serum when combined with hormonal contraceptives
may diminish the concentration of serum when combined with hormonal contraceptives
may diminish the concentration of serum when combined with indinavir
may diminish the concentration of serum when combined with larotrectinib
may diminish the concentration of serum when combined with lefamulin
may decrease the therapeutic effect of each other when combined
meningococcal A C Y and W polysaccharide tetanus toxoid conjugate vaccineÂ
efficacy of vaccines will be reduced when used along with vaccine administration, which should be avoided for at least two weeks before initiation of therapy
may diminish the serum concentration of each other when combined
may diminish the serum concentration of each other when combined
may diminish the serum concentration of each other when combined
may diminish the serum concentration of each other when combined
may diminish the serum concentration of each other when combined
may diminish the serum concentration of each other when combined
may diminish the serum concentration of each other when combined
may diminish the serum concentration of each other when combined
may diminish the serum concentration of each other when combined
may diminish the serum concentration of each other when combined
may increase the adverse effect of corticosteroids
may increase the adverse effect of corticosteroids
may diminish the concentration of serum when combined with antihepaciviral products
When prednisolone is used in combination with rabies vaccine, this leads to a reduction in the rabies vaccine effects through the process of pharmacodynamic antagonism
when prednisolone is used in combination with diphtheria & tetanus toxoids, this leads to a reduction in the effects of diphtheria & tetanus toxoids through pharmacodynamic antagonism
pneumococcal vaccine 13-valentÂ
prednisolone diminishes the efficacy of the 13-valent pneumococcal vaccine through pharmacodynamic antagonism
the effect of nivolumab decreases on interacting with prednisolone.
they decrease the concentration of lurbinectedin in the serum
avanafil: they may diminish the serum concentration of CYP3A4 Inducers
naxitinib: they may diminish the serum concentration of CYP3A4 Inducers
encorafenib: they may diminish the serum concentration of CYP3A4 Inducers
may enhance the concentration of serum when combined with CYP3A4 substrates
finerenone: they may diminish the serum concentration of CYP3A4 Inducers
infigratinib: they may diminish serum concentrations of CYP3A4 Inducers
lenacapavir: they may diminish the serum concentration of CYP3A4 Inducers
leniolisib: they may diminish the serum concentration of CYP3A4 Inducers
selpercatinib: they may diminish the serum concentration of CYP3A4 Inducers
selumetinib: they may diminish the serum concentration of CYP3A4 Inducers
sertraline: they may diminish the serum concentration of CYP3A4 Inducers
tazemetostat: they may diminish the serum concentration of CYP3A4 Inducers
may enhance the concentration of serum when combined with CYP3A4 substrates
may diminish the concentration of serum when combined with isavuconazonium sulfate
may diminish the concentration of serum when combined with abemaciclib
may diminish the serum concentration of each other when combined
they decrease the concentration of active metabolites of tamoxifen in serum
trabectedin: they may diminish the serum concentration of CYP3A4 Inducers
may diminish the serum concentration of each other when combined
may diminish the serum concentration of each other when combined
may increase the adverse effect of corticosteroids
may increase the adverse effect of corticosteroids
may increase the adverse effect of corticosteroids
may increase the adverse effect of corticosteroids
may increase the adverse effect of corticosteroids
may diminish the therapeutic effect of corticosteroids
may diminish the therapeutic effect of corticosteroids
may diminish the therapeutic effect of corticosteroids
may diminish the therapeutic effect of corticosteroids
may diminish the therapeutic effect of corticosteroids
may diminish the serum concentration of corticosteroids
may diminish the serum concentration of corticosteroids
may diminish the serum concentration of corticosteroids
may diminish the serum concentration of corticosteroids
may diminish the serum concentration of corticosteroids
may diminish the therapeutic effect of corticosteroids
bazedoxifene/conjugated estrogens
may diminish the therapeutic effect of corticosteroids
may diminish the therapeutic effect of corticosteroids
may diminish the therapeutic effect of corticosteroids
may diminish the therapeutic effect of corticosteroids
may diminish the therapeutic effect
may diminish the therapeutic effect
may diminish the therapeutic effect
may diminish the therapeutic effect
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may increase the risk of adverse effects
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
prednisolone: they may diminish the serum concentration of CYP3A4 Inducers
may reduce the levels of serum concentration
may reduce the levels of serum concentration
may reduce the levels of serum concentration
may reduce the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the serum concentration
may decrease the serum concentration
may decrease the serum concentration
may decrease the serum concentration
may decrease the serum concentration
may decrease the serum concentration
may decrease the serum concentration
may decrease the serum concentration
may decrease the serum concentration
may decrease the serum concentration
may decrease the serum concentration
may decrease the serum concentration
may decrease the serum concentration
may decrease the serum concentration
may decrease the serum concentration
may decrease the serum concentration
may decrease the serum concentration
may decrease the serum concentration
may decrease the serum concentration
may diminish the concentration of serum when combined with cannabis
may diminish the concentration of serum when combined with cannabis
may enhance the CNS depressant effect
may enhance the CNS depressant effect
may enhance the CNS depressant effect
may enhance the CNS depressant effect
may enhance the CNS depressant effect
may diminish serum concentrations of prednisone and its active metabolites
Strong CYP3A4 inducers may lower the serum concentration of alprazolam
Strong CYP3A4 inducers may decrease serum concentrations of the active metabolite(s) of amiodarone
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
may decrease the levels of serum concentration
amlodipine: they may diminish the serum concentration of CYP3A4 Inducers
isradipine: they may diminish the serum concentration of CYP3A4 Inducers
istradefylline: they may diminish the serum concentration of CYP3A4 inducers
may diminish the concentration of serum when combined with taurursodiol
ciprofloxacin inhaled (Pending FDA approval)Â
May increase the toxic effect of Quinolones
nilvadipine: they may diminish the serum concentration of CYP3A4 Inducers
nimodipine: they may diminish the serum concentration of CYP3A4 Inducers
sildenafil: they may diminish the serum concentration of CYP3A4 Inducers
tofacitinib: they may diminish the serum concentration of CYP3A4 Inducers
may enhance the serum concentration of each other when combined
it increases the concentration of CYP3A4 inducers in serum
It may enhance the serum concentration when combined with CYP3A4 Substrates
It may enhance the serum concentration when combined with CYP3A4 Substrates
buspirone: they may enhance the serum concentration of CYP3A Inhibitors
It may enhance the risk of adverse effects when combined with CYP3A4 inducers
rolapitant: they may diminish the serum concentration of CYP3A4 Inducers
brimonidine: they may diminish the serum concentration of CYP3A4 Inducers
methylphenidate: they may diminish the serum concentration of CYP3A4 Inducers
molsidomine: they may diminish the serum concentration of CYP3A4 Inducers
dimercaprol: they may diminish the serum concentration of CYP3A4 Inducers
may decrease the anti-neoplastic effect of each other when combined
betamethasone + salicylic acidÂ
may enhance the serum concentration of corticosteroids
tricyclic antidepressants: they may enhance the serum concentration of CYP3A4 inducers
cannabinoid receptor agonists: they may enhance the serum concentration of CYP3A4 inducers
cannabinoid receptor agonists: they may enhance the serum concentration of CYP3A4 inducers
inducing agents of the cytochrome P450 enzymes, such as rifampin and carbamazepine, can reduce the exposure and effectiveness of rimonabant
an increase in rate of metabolism may be seen
When prednisolone is used together in combination with profenamine, this leads to reduction in therapeutic effectiveness of profenamine
may decrease the level of serum concentration
may decrease the level of serum concentration
may decrease the level of serum concentration
may decrease the level of serum concentration
tenofovir disoproxil fumarate or tenofovir DFÂ
may decrease the level of serum concentration
tenofovir disoproxil fumarate or tenofovir DFÂ
may decrease the level of serum concentration
may decrease the level of serum concentration
may decrease the level of serum concentration
may decrease the level of serum concentration
Actions and Spectrum:
Mechanism of action
The action of prednisolone is through the inhibition of the activity of specific inflammatory cells, such as leukocytes and lymphocytes, and by reducing the production of inflammatory mediators, such as prostaglandins and leukotrienes. Prednisolone also has anti-inflammatory and immunosuppressant effects.
Spectrum
prednisolone has a broad spectrum of activity, including:
Anti-inflammatory: It reduces inflammation by inhibiting the activity of specific inflammatory cells, such as leukocytes and lymphocytes, and by reducing the production of inflammatory mediators, such as prostaglandins and leukotrienes.
Immunosuppressant: It suppresses the immune system, which can help to control autoimmune disorders, such as rheumatoid arthritis and lupus.
Anti-allergic: It blocks the release of certain chemicals in the body that cause allergic reactions, such as histamine and leukotrienes.
Anti-proliferative: It may inhibit cell growth and division, which can help treat certain types of cancer.
Frequency not defined
Adrenal suppression
Diabetes mellitus
Glucose intolerance
Hypokalemic alkalosis
Insomnia
Myopathy
Osteoporosis
Perianal pruritis
Pseudotumor cerebri
Seizure
Urticaria
Acne
Delayed wound healing
GI perforation
Hepatomegaly
Menstrual irregularity
Neuritis
Peptic ulcer
Psychosis
Vertigo
Black Box Warning:
prednisolone is a corticosteroid medication used to treat a variety of conditions such as allergies, inflammation, and autoimmune diseases. It works by reducing inflammation and suppressing the immune system.
Contraindications
Caution
Pregnancy consideration: Insufficient data available
Lactation: Excretion of the drug in human breast milk is known
Pregnancy category:
Category A: well-controlled and Satisfactory studies show no risk to the fetus in the first or later trimester.
Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women.
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.
Category D: adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.
Category N: There is no data available for the drug under this category
Pharmacology
It binds to specific glucocorticoid receptors in the body, leading to gene expression changes and protein synthesis control. This leads to the suppression of inflammation and the control of the rate of protein synthesis, which is an integral part of the inflammatory response.
It also suppresses the migration of polymorphonuclear leukocytes (PMNs) and fibroblasts, cells that play an essential role in the inflammatory response. This can help reduce the number of cells present at the site of inflammation, which can help reduce inflammation and swelling.
It also reverses capillary permeability, which can help reduce fluid leakage from blood vessels at the site of inflammation. This can also help to reduce inflammation and swelling.
Pharmacodynamics
It has a wide range of effects on the body, and its effects are primarily dependent on the dose and duration of treatment. It should be used under the direction of a healthcare provider, and regular monitoring is necessary to avoid potential side effects and ensure the treatment’s effectiveness.
Pharmacokinetics
Absorption
It is rapidly absorbed after oral administration, with peak plasma concentrations occurring within 1 hour. However, the duration of action is longer, 18-36 hours.
Distribution
It is highly protein-bound in the bloodstream, with a protein binding range of 65-91%. However, this percentage can be lower in elderly patients. The volume of distribution (Vd) is relatively small, at 0.22-0.7 L/kg.
Metabolism
It is extensively metabolized in the liver, but the specific metabolic pathways are not well understood.
Elimination/excretion
The elimination half-life of prednisolone is relatively short, at 3.6 hours in patients with normal renal function and 3-5 hours in patients with end-stage renal disease. The drug is not dialyzable, meaning it cannot be removed from the body by hemodialysis. The renal clearance of the drug is 9.5 mL/min, and it is excreted primarily in the urine.
Administration
It is a steroid medication often used to reduce inflammation and swelling in the body. It can be administered orally (by mouth) or intravenously (into a vein). The dosage and frequency of administration will depend on the condition being treated and the response to the medication.
It is essential to follow the dosing instructions provided by a healthcare provider and to not abruptly stop taking prednisolone, as this can cause withdrawal symptoms.
Patient information leaflet
Generic Name: prednisolone
Pronounced: (pred·ni·suh·lone)
Why do we use prednisolone?
prednisolone is sometimes used in the treatment of alcoholic liver disease because it has anti-inflammatory and immunosuppressive effects that can help to reduce liver inflammation and damage caused by the disease.
Alcoholic liver disease is a condition that occurs when excessive alcohol consumption leads to liver damage, inflammation, and scarring. The immune system is also involved in this process, as it responds to the inflammation and can further damage the liver tissue. prednisolone works by suppressing the immune response and reducing inflammation, which can help to slow down the progression of the disease and improve liver function.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
